CFGS
OTLK icon

Concourse Financial Group Securities’s Outlook Therapeutics OTLK Stock Holding History

Concourse Financial Group Securities’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-69
Closed -$2.15K – 2363
2021
Q4 		$2K Hold
69
– – ﹤0.01% 2215
2021
Q3 		$3K Hold
69
– – ﹤0.01% 2188
2021
Q2 		$3K Hold
69
– – ﹤0.01% 2146
2021
Q1 		$3K Hold
69
– – ﹤0.01% 2075
2020
Q4 		$2K Hold
69
– – ﹤0.01% 2108
2020
Q3 		$1K Hold
69
– – ﹤0.01% 2098
2020
Q2 		$2K Hold
69
– – ﹤0.01% 1921
2020
Q1 		$1K Buy
+69
New +$1.14K ﹤0.01% 2065

Other funds holding OTLK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
VF
Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Concourse Financial Group Securities's OTLK Position: Q1 2022 in Review

Concourse Financial Group Securities sold out of Outlook Therapeutics (OTLK) in Q1 2022, closing a stake of 69 shares — an estimated $2.15K sold.

Concourse Financial Group Securities first reported a position in OTLK in Q1 2020 and held it in 8 quarters. The position peaked at $3K in Q3 2021. 73 funds tracked by Wall St. Rank hold OTLK as of Q1 2022.

  • Concourse Financial Group Securities reported no remaining Outlook Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Concourse Financial Group Securities sold 69 Outlook Therapeutics shares in Q1 2022, an estimated $2.15K.
  • Concourse Financial Group Securities first reported a position in Outlook Therapeutics in Q1 2020 and held it in 8 quarters.
  • Concourse Financial Group Securities's Outlook Therapeutics position peaked at $3K in Q3 2021.
  • 73 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2022.

Based on Concourse Financial Group Securities's 13F filing for Q1 2022, filed 9 May 2022.